All In Biotech

Drug Trial Radar · NCT03142893

Hormonal Mechanisms of Sleep Restriction - Axis Study

Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 8, 2017

Primary completion

Oct 30, 2020

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Peter y. LiuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 22 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.

Conditions

  • Sleep Restriction

Interventions

  • Ketoconazole PillDrug

    Ketoconazole pill is taken 4 times per Inpatient Stay

  • GanirelixDrug

    Ganirelix subcutaneous injection is administered twice per Inpatient Stay

  • DexamethasoneDrug

    Dexamethasone Pills is taken twice per Inpatient Stay

  • Dexamethasone InjectionDrug

    Dexamethasone IV injection is given twice per Inpatient Stay

  • Cosyntropin Injectable ProductDrug

    cosyntropin injection is given twice per Inpatient Stay

  • Recombinant Human Luteinizing HormoneDrug

    Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit

  • Hydrocortisone InjectionDrug

    Hydrocortisone IV push is given twice per Inpatient Visit

  • GonadorelinDrug

    Gonadorelin IV injection is given twice per Inpatient Stay

  • CorticorelinDrug

    Corticorelin IV injection is given twice per Inpatient Stay

  • Placebo oral capsuleDrug

    Placebo for ketoconazole are given 4 times per Inpatient Stay

  • Saline SolutionDrug

    Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay

  • Saline Solution for InjectionDrug

    Saline Solution (placebo) for ganirelix subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Blood Cortisol ConcentrationTime frame: 5 days
  2. Average Blood Testosterone ConcentrationTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Los Angeles Biomedical Research Institute

    Torrance, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.